

FINAL COMMUNICATION OF THE STABILIZATION ACTIVITY AND EXERCISE OF THE GREENSHOE OPTION

Castronno (VA), 11 December 2025 - Più Medical S.p.A. (“Più Medical” or the “Company”), consolidation platform with a *buy-fix-scale* model active in the retail pharmacy sector and focused, as of the date of this press release, on the Lombardy region – announces that today Banca Investis S.p.A. (“Investis”), acting as stabilisation agent, also on behalf of the Joint Bookrunners, has partially exercised the *Greenshoe* Option granted by shareholders G.S.M. S.r.l. and La Farmaceutica S.p.A. (collectively, the “Selling Shareholders”) for a total of 204.500 ordinary shares of the Company (the “Shares”).

The *Greenshoe* Option was exercised at a price of €6,00 per share, equal to the price of the placement prior to Più Medical's IPO, for a total value of €1.227.000. Taking into account the exercise of the *Greenshoe* Option, the free float now amounts to 21,27% of the share capital and 14,47% of the voting rights.

Payment for the Shares subject to the *Greenshoe* option and the return to the Selling Shareholders of the 70.500 Shares loaned pursuant to the *Over-allotment* option will take place on December 16, 2025.

Following the exercise of the *Greenshoe* Option, the offering therefore involved 2.154.500 ordinary shares (of which 1.700.000 were newly issued), for a total value of €12,9 million.

The following table shows the composition of Più Medical's share capital as of today's date, following the exercise of the *Greenshoe* Option, indicating the number of shares held by shareholders, the relevant category, and the respective percentage of total share capital and total voting rights:

Shareholders	n. Ordinary shares	n. Multiple voting shares	% of share capital	% of voting rights
G.S.M. S.r.l.	3.115.228	259.881	50,37%	58,01%
La Farmaceutica S.p.A.	280.272	90.119	5,53%	12,00%
V.F. Pharma S.r.l.	1.600.000	-	23,88%	16,24%
Market	1.354.500	-	20,22%	13,75%
TOTAL	6.350.000	350.000	100%	100%

The stabilization period ends immediately upon exercise of the *Greenshoe* Option.

Più Medical, based on information provided by Banca Investis S.p.A. in its capacity as the entity responsible for stabilization activities in connection with the offering of Più Medical ordinary shares on Euronext Growth Milan - announces that Investis has carried out stabilization transactions (as defined in Article 3, paragraph 2, letter d) of the Market Abuse Regulation (EU/596/2014) in relation to the offering of financial instruments described below.



Issuer:	Più Medical S.p.A.
Financial instruments	Ordinary Shares ISIN IT0005676140
Offering size	1.950.000
Total number of shares subject to stabilization	275.000
Entity in charge of the stabilization activities	Banca Investis S.p.A.

Pursuant to Article 6, paragraph 2 of Delegated Regulation (EU) 2016/1052 supplementing Regulation (EU) No. 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards on the conditions applicable to share buy-back programs and stabilization measures, Più Medical, based on information provided by Investis, announces that stabilization activities began on November 20, 2025, and that the last stabilization operation took place on [December 9, 2025].

The following table shows the data relating to the transactions carried out during the stabilization period.

Stabilization transactions

Date	Total number of ordinary shares purchased	Number of transactions	Price range (EUR)	Trading venue
20/11/2025	17.000	13	5,74 – 5,84	Borsa Italiana - Euronext Growth Milan
21/11/2025	14.000	17	5,76 – 5,94	Borsa Italiana - Euronext Growth Milan
24/11/2025	10.250	18	5,87 – 5,95	Borsa Italiana - Euronext Growth Milan
25/11/2025	6.000	10	5,93 – 5,95	Borsa Italiana - Euronext Growth Milan
27/11/2025	2.250	3	5,85 – 5,94	Borsa Italiana - Euronext Growth Milan
28/11/2025	2.250	5	5,90 – 5,90	Borsa Italiana - Euronext Growth Milan
01/12/2025	2.500	5	5,93 – 5,95	Borsa Italiana - Euronext Growth Milan



02/12/2025	3.250	7	5,90 – 5,95	Borsa Italiana - Euronext Growth Milan
03/12/2025	1.750	4	5,89 – 5,90	Borsa Italiana - Euronext Growth Milan
04/12/2025	2.250	5	5,88 – 5,90	Borsa Italiana - Euronext Growth Milan
05/12/2025	2.250	5	5,9 – 5,95	Borsa Italiana - Euronext Growth Milan
08/12/2025	500	1	5.901	Borsa Italiana - Euronext Growth Milan
09/12/2025	500	1	5.95	Borsa Italiana - Euronext Growth Milan

This press release is also issued on behalf of Banca Investis pursuant to Article 6(2) of Delegated Regulation (EU) 2016/1052.

For further information on Più Medical and the initial offering, please refer to the Admission Document published on November 18, 2025. The Admission Document is available on the website www.piumedical.com, in the “Investor Relations/IPO EGM” section.

The press release is available on the Company's website www.piumedical.com, in the “Investor Relations/Press Releases” section and at www.emarketstorage.it.

For the transmission and storage of Regulated Information, Più Medical uses the authorized SDIR eMarket Storage circuit (www.emarketstorage.it), managed by Teleborsa S.r.l. - with headquarters in Piazza di Priscilla, 4 - Rome.

CONTACTS

Investor Relator

Fabio Luigi Giordano
Viale Lombardia 62, 21040 Castronno (VA)
+39 0332 896059
investor@piumedical.com

Euronext Growth Advisor

Value track SIM S.p.A.
Via Masaccio 172/174, Firenze
ecm@value-track.vom

Specialist

Banca Investis S.p.A.
Via Broletto, 5, 20121 Milano
+ 39 0299968127
marco.pelosi@bancainvestis.com

MEDIA RELATIONS

Twister Communications Group
Via Valparaiso, 3 - 20144 Milano
Tel. +39 02438114200
Lucia Saluzzi, Luca Di Bitetto piumedical@twistergroup.it





The Company

Più Medical is a consolidation platform with a buy-fix-scale model, established in 2025 and focused on the retail pharmacy sector in Northern Italy. The Group currently manages a network of 16 pharmacies. The Group's activity focuses on the management and enhancement of local pharmacies through a centralized operating model that integrates industrial, managerial, and commercial expertise. Più Medical is characterized by an approach geared towards efficiency and profitability, based on structured processes, economies of scale, and a governance model capable of supporting future growth.

